Why the study?
Is aspirin, clopidogrel, or both more cost-effective for secondary prevention of coronary heart disease?
Is aspirin, clopidogrel, or both more cost-effective for secondary prevention of coronary heart disease?
Aspirin remains the most cost-effective first-line antiplatelet therapy for secondary prevention of coronary heart disease, with clopidogrel reserved for aspirin-ineligible patients.
May inform resource allocation favoring aspirin in secondary prevention; leaves open updates with contemporary pricing and agents.
Increased prescription of aspirin for secondary prevention of coronary heart disease is attractive from a cost-effectiveness perspective. Because clopidogrel is more costly, its incremental cost effectiveness is currently unattractive, unless its use is restricted to patients who are ineligible for aspirin.
No takes yet. Share an insight, caveat, or question.
Gaspoz et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: